Cutler Group LP Corvus Pharmaceuticals, Inc. Call Options Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$0.87 - $2.03 $174 - $405	-200 Closed	0 $0
Q1 2022 Apr 14, 2022	SELL	$1.46 - $2.48 $24,528 - $41,664	-16,800 Reduced 98.82%	200 $0
Q4 2021 Jan 18, 2022	SELL	$2.34 - $5.31 $506,375 - $1.15 Million	-216,400 Reduced 92.72%	17,000 $0
Q3 2021 Oct 26, 2021	BUY	$1.89 - $8.53 $439,425 - $1.98 Million	232,500 Added 25833.33%	233,400 $38,000
Q4 2020 Jan 21, 2021	SELL	$3.56 - $4.86 $1,780 - $2,430	-500 Reduced 35.71%	900 $0
Q3 2020 Oct 27, 2020	BUY	$2.6 - $5.37 $3,640 - $7,518	1,400 New	1,400 $0

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $417M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.